|
SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes 14-May-2024 / 18:03 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. SCHOTT Pharma see FY 25 impacted by slower growth from syringes For its fiscal year 2024/2025, beginning 1st October 2024, the company is forecasting a revenue growth in a high single-digit to a low double-digit percentage range, which deviates from the current market consensus. Due to the revenue growth that is lower than previously expected, the EBITDA margin expansion will be weaker than currently expected in the market. These forecasts are based on constant currencies. The reason for the expected development in fiscal year 2024/2025 is a lower demand for syringes of a large customer. Despite this temporary effect, the company confirms its mid-term forecast. The company also confirms its forecast for the current fiscal year. Investor contact Jasko Terzic, CFA Senior Investor Relations Manager E-Mail: ir.pharma@schott.com Press contact Joana Kornblum Media Relations Tel.: +49 151/29223552 E-Mail: joana.kornblum@schott.com End of Inside Information 14-May-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Investigational BTK Inhibitor Shows Efficacy in Chronic Spontaneous Urticaria
Remibrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, was safe and efficacious in patients with chronic spontaneous urticaria (CSU), a phase IIb extension study showed.
October 25, 2023